Strategic partnerships Takeda’s recent termination of their neurodegenerative collaboration with Denali signals a potential re-engagement or replacement partner opportunity for Denali to pursue new pharma collaborations, licensing, or co-development deals to advance their programs.

Neurodegenerative focus Denali’s TransportVehicle platform and ongoing programs targeting CNS diseases and related lysosomal storage disorders position them to engage with large biotech and pharma companies seeking CNS delivery capabilities, potentially enabling co-development or platform licensing opportunities.

Commercialized asset AVLAYAH (tividenofusp alfa-eknm) for MPS II has presymptomatic and pediatric indications with exclusive specialty pharmacy partnerships, indicating a path to expand payer conversations, access strategies, and global commercialization partnerships.

Financial strength With substantial funding and recent revenue growth driven by milestones and collaborations, Denali is well-positioned to pursue strategic partnerships, co-development financing, and milestone-backed deals to advance pipeline programs.

Clinical momentum Ongoing and upcoming clinical developments such as DNL593 and DNL343 trial updates, alongside leadership movement, suggest opportunities to engage in alliance discussions around study expansion, data-sharing collaborations, and joint access to trial networks.